Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

CRISPR Therapeutics

Nasdaq:CRSP
Snowflake Description

Flawless balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CRSP
Nasdaq
$3B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • CRISPR Therapeutics has significant price volatility in the past 3 months.
CRSP Share Price and Events
7 Day Returns
7.3%
NasdaqGM:CRSP
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
17.1%
NasdaqGM:CRSP
0%
US Biotechs
-11.5%
US Market
CRSP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CRISPR Therapeutics (CRSP) 7.3% -15.4% -36.6% 17.1% 92.1% -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • CRSP outperformed the Biotechs industry which returned 0% over the past year.
  • CRSP outperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
CRSP
Industry
5yr Volatility vs Market

CRSP Value

 Is CRISPR Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CRISPR Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $41.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CRISPR Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CRISPR Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CRSP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $1.23
NasdaqGM:CRSP Share Price ** NasdaqGM (2020-03-27) in USD $41.82
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CRISPR Therapeutics.

NasdaqGM:CRSP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CRSP Share Price ÷ EPS (both in USD)

= 41.82 ÷ 1.23

34.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CRISPR Therapeutics is overvalued based on earnings compared to the US Biotechs industry average.
  • CRISPR Therapeutics is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does CRISPR Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:CRSP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 34.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts
-2.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

NasdaqGM:CRSP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 34.02x ÷ -2.1%

-16.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CRISPR Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CRISPR Therapeutics's assets?
Raw Data
NasdaqGM:CRSP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $15.46
NasdaqGM:CRSP Share Price * NasdaqGM (2020-03-27) in USD $41.82
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:CRSP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CRSP Share Price ÷ Book Value per Share (both in USD)

= 41.82 ÷ 15.46

2.71x

* Primary Listing of CRISPR Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CRISPR Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess CRISPR Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CRISPR Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CRSP Future Performance

 How is CRISPR Therapeutics expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-2.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CRISPR Therapeutics expected to grow at an attractive rate?
  • CRISPR Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 1.7%.
Growth vs Market Checks
  • CRISPR Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • CRISPR Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CRSP Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CRSP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts -2.1%
NasdaqGM:CRSP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts 19.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CRSP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CRSP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 509 -271 -72 6
2023-12-31 146 -240 -287 6
2022-12-31 45 -273 -335 9
2021-12-31 21 -274 -326 13
2020-12-31 14 -228 -269 13
2020-03-28
NasdaqGM:CRSP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 290 57 67
2019-09-30 213 25 -11
2019-06-30 1 -128 -200
2019-03-31 2 -117 -185
2018-12-31 3 -96 -165
2018-09-30 35 -83 -117
2018-06-30 37 -79 -91
2018-03-31 40 -69 -75
2017-12-31 41 -70 -68
2017-09-30 11 -75 -51
2017-06-30 10 -71 -41
2017-03-31 7 -69 -36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CRISPR Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • CRISPR Therapeutics's revenue is expected to grow by 19.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CRSP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below

All data from CRISPR Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CRSP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.07 2.08 -4.46 6.00
2023-12-31 -3.94 -2.11 -4.95 6.00
2022-12-31 -4.97 -3.04 -6.35 8.00
2021-12-31 -4.94 -3.49 -7.14 12.00
2020-12-31 -4.44 -3.34 -5.33 12.00
2020-03-28
NasdaqGM:CRSP Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 1.23
2019-09-30 -0.21
2019-06-30 -3.92
2019-03-31 -3.74
2018-12-31 -3.44
2018-09-30 -2.60
2018-06-30 -2.11
2018-03-31 -1.81
2017-12-31 -1.71
2017-09-30 -1.35
2017-06-30 -1.41
2017-03-31 -1.74

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CRISPR Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CRISPR Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CRISPR Therapeutics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CRSP Past Performance

  How has CRISPR Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CRISPR Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CRISPR Therapeutics's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • CRISPR Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • CRISPR Therapeutics has become profitable in the last year making it difficult to compare the US Biotechs industry average.
Earnings and Revenue History
CRISPR Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CRISPR Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CRSP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 289.59 66.86 63.49
2019-09-30 212.69 -11.27 62.76
2019-06-30 1.32 -200.41 57.41
2019-03-31 2.09 -185.09 54.39
2018-12-31 3.12 -164.98 48.29
2018-09-30 35.33 -117.25 43.08
2018-06-30 37.16 -91.25 41.01
2018-03-31 39.65 -75.18 36.04
2017-12-31 41.00 -68.36 35.85
2017-09-30 11.02 -51.40 34.60
2017-06-30 10.18 -41.37 30.60
2017-03-31 7.39 -36.21 31.58
2016-12-31 5.16 -23.18 31.06
2016-09-30 3.07 -52.55 25.21
2016-06-30 1.52 -44.22 23.56
2016-03-31 0.72 -30.71 16.95
2015-12-31 0.25 -25.50 13.40
2014-12-31 -7.01 5.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • CRISPR Therapeutics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • CRISPR Therapeutics used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.
  • CRISPR Therapeutics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess CRISPR Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CRISPR Therapeutics has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CRSP Health

 How is CRISPR Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CRISPR Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CRISPR Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CRISPR Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CRISPR Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • CRISPR Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CRISPR Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:CRSP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 939.43 0.00 943.77
2019-09-30 591.88 0.00 629.72
2019-06-30 367.68 0.00 427.89
2019-03-31 379.81 0.00 437.55
2018-12-31 392.20 0.00 456.65
2018-09-30 417.31 0.00 487.30
2018-06-30 265.15 0.00 319.74
2018-03-31 290.34 0.00 341.77
2017-12-31 187.83 0.00 239.76
2017-09-30 178.96 0.00 253.52
2017-06-30 197.80 0.00 272.26
2017-03-31 215.18 0.00 288.87
2016-12-31 232.85 0.00 315.52
2016-09-30 123.03 0.00 228.61
2016-06-30 135.34 0.00 246.85
2016-03-31 89.90 0.00 200.60
2015-12-31 35.40 38.34 155.96
2014-12-31 -0.70 0.00 0.95
  • CRISPR Therapeutics has no debt.
  • CRISPR Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • CRISPR Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • CRISPR Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess CRISPR Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CRISPR Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CRSP Dividends

 What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CRISPR Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of CRISPR Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CRISPR Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CRISPR Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CRSP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CRSP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CRISPR Therapeutics has not reported any payouts.
  • Unable to verify if CRISPR Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CRISPR Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CRISPR Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of CRISPR Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess CRISPR Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CRISPR Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CRISPR Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CRSP Management

 What is the CEO of CRISPR Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sam Kulkarni
COMPENSATION $9,727,531
AGE 40
TENURE AS CEO 3.2 years
CEO Bio

Dr. Samarth Kulkarni, also known as Sam, Ph.D., serves as an Independent Director at Repare Therapeutics Inc. since December 2019. Dr Kulkarni has been the Chief Executive Officer of CRISPR Therapeutics AG since December 1, 2017 and served as its President since May 4, 2017 until December 1, 2017 and its Chief Business Officer since August 2015. He serves as Director at Black Diamond Therapeutics, Inc. since December, 2019. He also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer.He serves as Director of CRISPR Therapeutics AG. He is the Independent Director at Aset Therapeutics, Inc. since December 5, 2019. Dr. Kulkarni served as an Acting Principal Financial Officer of CRISPR Therapeutics AG since March 30, 2017 until November 2017 and served as its Principal Financial Officer since March 21, 2017. Dr. Kulkarni joined CRISPR Therapeutics from McKinsey and Company, where he was a Partner and had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in cutting edge areas such as personalized medicine and immunotherapy, where he co-authored several publications. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, which has been published in several leading journals. Dr. Kulkarni has a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology.

CEO Compensation
  • Sam's compensation has increased in line with CRISPR Therapeutics recently becoming profitable.
  • Sam's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the CRISPR Therapeutics management team in years:

2.6
Average Tenure
52
Average Age
  • The tenure for the CRISPR Therapeutics management team is about average.
Management Team

Rodger Novak

TITLE
Founder
COMPENSATION
$646K
AGE
52
TENURE
2.3 yrs

Sam Kulkarni

TITLE
CEO & Director
COMPENSATION
$10M
AGE
40
TENURE
3.2 yrs

Mike Tomsicek

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
53
TENURE
2.3 yrs

James Kasinger

TITLE
General Counsel & Secretary
COMPENSATION
$3M
AGE
47
TENURE
2.8 yrs

Tony Ho

TITLE
Executive Vice President of Research & Development
COMPENSATION
$4M
AGE
53
TENURE
2.6 yrs

Shaun Foy

TITLE

Emmanuelle Charpentier

TITLE
Co-Founder & Scientific Advisory Board Member

Craig Mello

TITLE
Scientific Founder & Advisory Board Member

Chad Cowan

TITLE
Scientific Founder

Matthew Porteus

TITLE
Scientific Founder & Advisory Board Member
Board of Directors Tenure

Average tenure and age of the CRISPR Therapeutics board of directors in years:

2.3
Average Tenure
47.5
Average Age
  • The average tenure for the CRISPR Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rodger Novak

TITLE
Founder
COMPENSATION
$646K
AGE
52
TENURE
2.3 yrs

Sam Kulkarni

TITLE
CEO & Director
COMPENSATION
$10M
AGE
40

Emmanuelle Charpentier

TITLE
Co-Founder & Scientific Advisory Board Member

Craig Mello

TITLE
Scientific Founder & Advisory Board Member

Matthew Porteus

TITLE
Scientific Founder & Advisory Board Member

Dan Anderson

TITLE
Scientific Founder & Advisory Board Member

Bill Lundberg

TITLE
Head of Scientific Advisory Board
COMPENSATION
$3M
AGE
56
TENURE
2.1 yrs

Simeon George

TITLE
Independent Director
COMPENSATION
$644K
AGE
42
TENURE
4.9 yrs

John Greene

TITLE
Independent Director
AGE
53
TENURE
0.8 yrs

Ali Behbahani

TITLE
Independent Director
COMPENSATION
$647K
AGE
43
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
24. Jan 20 Sell Bayer Aktiengesellschaft Company 09. Jan 20 17. Jan 20 -632,105 $62.24 $-37,954,929
10. Jan 20 Sell Bayer Aktiengesellschaft Company 18. Dec 19 08. Jan 20 -1,389,030 $68.02 $-87,126,756
X
Management checks
We assess CRISPR Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CRISPR Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CRSP News

Simply Wall St News

Could The CRISPR Therapeutics AG (NASDAQ:CRSP) Ownership Structure Tell Us Something Useful?

CRISPR Therapeutics has a market capitalization of US$2.6b, so we would expect some institutional investors to have noticed the stock. … Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … See our latest analysis for CRISPR Therapeutics NasdaqGM:CRSP Ownership Summary, July 17th 2019 What Does The Institutional Ownership Tell Us About CRISPR Therapeutics?

Simply Wall St -

The CRISPR Therapeutics (NASDAQ:CRSP) Share Price Is Down 35% So Some Shareholders Are Getting Worried

While not a mind-blowing move, it is good to see that the CRISPR Therapeutics AG (NASDAQ:CRSP) share price has gained 21% in the last three months. … View our latest analysis for CRISPR Therapeutics CRISPR Therapeutics recorded just US$2,094,000 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. … A Different Perspective Given that the market gained 3.5% in the last year, CRISPR Therapeutics shareholders might be miffed that they lost 35%.

Simply Wall St -

What Should We Expect From CRISPR Therapeutics AG's (NASDAQ:CRSP) Earnings Over The Next Few Years?

CRISPR Therapeutics AG's (NASDAQ:CRSP) announced its latest earnings update in December 2018, which … company earnings became less negative compared to the previous year's level

Simply Wall St -

Is CRISPR Therapeutics AG (NASDAQ:CRSP) As Strong As Its Balance Sheet Indicates?

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as CRISPR Therapeutics AG (NASDAQ:CRSP), with a market capitalization of US$2.0b, rarely draw their attention from the investing community. … Let’s take a look at CRSP’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Is CRSP’s debt level acceptable?

Simply Wall St -

Can We See Significant Institutional Ownership On The CRISPR Therapeutics AG (NASDAQ:CRSP) Share Register?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that have been privatized tend to have low insider ownership. … With a market capitalization of US$1.4b, CRISPR Therapeutics is a decent size, so it is probably on the radar of institutional investors.

Simply Wall St -

What does CRISPR Therapeutics AG's (NASDAQ:CRSP) Balance Sheet Tell Us About Its Future?

The direct benefit for CRISPR Therapeutics AG (NASDAQ:CRSP), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is CRSP will have to adhere to stricter debt covenants and have less financial flexibility. … Is CRSP right in choosing financial flexibility over lower cost of capital.

Simply Wall St -

Analysts Expect Breakeven For CRISPR Therapeutics AG (NASDAQ:CRSP)

The company’s loss has recently broadened since it announced a -US$68.36m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$75.18m, moving it further away from breakeven … Many investors are wondering the rate at which CRSP will turn a profit, with the big question being “when will the company breakeven?” … I’ve put together a brief outline of industry analyst expectations for CRSP, its year of breakeven and its implied growth rate.

Simply Wall St -

CRISPR Therapeutics AG (NASDAQ:CRSP): Financial Strength Analysis

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as CRISPR Therapeutics AG (NASDAQ:CRSP), with a market capitalization of US$2.36B, rarely draw their attention from the investing community. … Today we will look at CRSP’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Note that this information is centred entirely on financial health and is a top-level understanding, so I encourage you to look further into CRSP here.

Simply Wall St -

Does CRISPR Therapeutics AG's (NASDAQ:CRSP) Earnings Growth Make It An Outperformer?

Assessing CRISPR Therapeutics AG's (NASDAQ:CRSP) performance as a company requires looking at more than just a years' earnings data. … Below, I will run you through a simple sense check to build perspective on how CRISPR Therapeutics is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its biotechnology industry peers. … Check out our latest analysis for CRISPR Therapeutics Did CRSP beat its long-term earnings growth trend and its industry?

Simply Wall St -

CRISPR Therapeutics AG (NASDAQ:CRSP): Earnings Growth Remains Elusive

The most recent earnings update CRISPR Therapeutics AG's (NASDAQ:CRSP) released in September 2017 confirmed company earnings became less negative compared to the previous year's level - great news for investors Below, I've laid out key growth figures on how market analysts view CRISPR Therapeutics's earnings growth outlook over the next few years and whether the future looks brighter. … See our latest analysis for CRISPR Therapeutics Analysts' expectations for next year seems pessimistic, with earnings becoming even more negative, generating $-114.0M in 2018. … This means that, we can anticipate CRISPR Therapeutics will chip away at a rate of -19.54% every year for the next couple of years.

Simply Wall St -

CRSP Company Info

Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Details
Name: CRISPR Therapeutics AG
CRSP
Exchange: NasdaqGM
Founded:
$2,544,567,508
60,845,708
Website: http://www.crisprtx.com
Address: CRISPR Therapeutics AG
Baarerstrasse 14,
Zug,
Zug, 6300,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CRSP Common Shares Nasdaq Global Market US USD 19. Oct 2016
DB 1CG Common Shares Deutsche Boerse AG DE EUR 19. Oct 2016
LSE 0VRQ Common Shares London Stock Exchange GB USD 19. Oct 2016
Number of employees
Current staff
Staff numbers
304
CRISPR Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:55
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/02/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.